Usage Examples
- The IND-enabling package is closed; we are drafting the integrated summary of toxicological effects now.
- Our IND-enabling tox is 28-day repeat-dose in rat and dog, which covers the dosing period in the Phase 1 protocol.
- Two of the IND-enabling studies were exploratory and non-GLP, so we state the reason in the pharmacology and toxicology section.
What is IND-Enabling Studies?
IND-enabling studies are the nonclinical pharmacology, toxicology and ADME work a sponsor runs to support the conclusion that human dosing is reasonably safe, distinguishing them from exploratory discovery studies never submitted to FDA.
IND-enabling studies exist because no one has ever taken the drug. FDA's only basis for permitting a first dose is animal and in vitro evidence, which is why 21 CFR 312.23(a)(8) asks for adequate pharmacological and toxicological information on which the sponsor has concluded that the proposed clinical investigations are reasonably safe. The nonclinical package stands in for human experience that does not yet exist.
IND-enabling studies cover pharmacological effects and mechanism of action, absorption, distribution, metabolism and excretion where known, and an integrated summary of toxicological effects in animals and in vitro. The boundary sits at both ends: they are not the CMC package, not the clinical protocol, and not the discovery screening that never leaves the lab notebook because it was never meant to support a safety conclusion.
IND-enabling studies are applied as an argument, not a checklist. The regulation names categories of toxicity testing as appropriate rather than fixing protocols, so the sponsor picks species, duration and endpoints, runs the pivotal work under Part 58, and defends those choices in the integrated summary. Reviewers then test whether the package supports the exact dose, duration and population proposed.
Not to be confused with
- Preclinical studies
- preclinical describes everything before human dosing, including discovery screens no one will ever file. IND-enabling studies are the subset assembled to support the safety conclusion and submitted under 21 CFR 312.23(a)(8).
- GLP studies
- GLP is a conduct standard, not a study type. Part 58 governs how a nonclinical laboratory study is run and documented; whether a given study belongs in the IND-enabling package is a separate question.
- Module 4
- Module 4 is where the nonclinical reports sit in the CTD. IND-enabling studies are the work itself. Same content, different question: what was done versus where it is filed.
- ICH M3(R2)
- M3(R2) is harmonised guidance on nonclinical safety studies for the conduct of human clinical trials. 21 CFR 312.23 is the binding US requirement. Guidance shapes the design; the regulation is what the IND is judged against.
The regulation sets a conclusion that must be supported, not a protocol list. These are the obligations that attach to it.
What you must do
- 1Submit adequate pharmacological and toxicological information on the basis of which you concluded it is reasonably safe to conduct the proposed clinical investigations21 CFR 312.23(a)(8)
- 2Describe the pharmacological effects and mechanism of action in animals, plus absorption, distribution, metabolism and excretion where known21 CFR 312.23(a)(8)(i)
- 3Run the pivotal safety studies under good laboratory practices, since Part 58 applies to nonclinical laboratory studies intended to support an application for a research permit21 CFR 58.1
- 4State, for each study subject to Part 58, that it complied with GLP, or give a brief statement of the reason for the noncompliance21 CFR 312.23(a)(8)(iii)
- 5Carry enough information into the IND for FDA to assess subject risk, because an insufficient package is itself a ground for clinical hold alongside unreasonable and significant risk of illness or injury21 CFR 312.42(b)(1)
Common mistakes
Copying another program's study list
21 CFR 312.23(a)(8) asks for a conclusion the data supports, not a fixed set of protocols. A package cloned from a competitor whose dose, duration or population differs produces data that does not answer the question the reviewer is actually asking, and the gap surfaces after the money is spent.
Filing study reports instead of an integrated summary
the regulation calls for an integrated summary of toxicological effects in animals and in vitro. Handing over a stack of standalone reports and leaving the reviewer to synthesize them converts a written argument into an information request, and the sponsor loses the chance to frame its own safety case.
Leaving GLP status ambiguous
Part 58 compliance is declared study by study, and noncompliance is permitted only with a brief statement of the reason. A missing or vague statement forces the reviewer to treat pivotal data as unqualified. The fix costs a paragraph before filing and a hold cycle after it.
When This Matters
- The IND-enabling package is closed; we are drafting the integrated summary of toxicological effects now.
- Our IND-enabling tox is 28-day repeat-dose in rat and dog, which covers the dosing period in the Phase 1 protocol.
- Two of the IND-enabling studies were exploratory and non-GLP, so we state the reason in the pharmacology and toxicology section.
Frequently Asked Questions
The pivotal safety studies do; exploratory studies do not. 21 CFR 58.1 applies good laboratory practices to nonclinical laboratory studies supporting applications for research permits. For each study subject to Part 58, the IND must state that it complied, or give a brief statement of the reason for noncompliance.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
Related Regulatory Intelligence
Related Actions
Sources & References
- 21 CFR 312.23 - IND content and format (CFR full text)
- 21 CFR 312.42 - Clinical holds and requests for modification (CFR full text)
- 21 CFR 58.1 - Good Laboratory Practice for Nonclinical Laboratory Studies, scope (CFR full text)
- ICH M3(R2) - Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
